Arcutis Biotherapeutics, Inc.
ARQT Healthcare Biotechnology
Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024. In the quarter to June 2026, revenue grew 59.3%, EPS grew 184.6%, free cash flow grew 228.0% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
Follow ARQT
Arcutis Biotherapeutics, Inc. (ARQT) Altman Z-score
Arcutis Biotherapeutics, Inc.'s Altman Z-score for fiscal 2025 is 6.98, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 6.98 | 5.97 |
| FY2024 | 1.01 | 5.66 |
| FY2023 | −4.65 | (3.31) |
| FY2022 | −1.34 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.65 | — | 0.78 | |
| Retained earnings / total assets | (2.63) | — | −3.68 | |
| EBIT / total assets | (0.03) | — | −0.09 | |
| Market value of equity / total liabilities | 15.17 | — | 9.10 | |
| Sales / total assets | 0.87 | — | 0.87 | |
| Altman Z-score | Safe zone | 6.98 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −3.68 | ||
Z and Z″ put Arcutis Biotherapeutics, Inc. in different zones: safe zone by Z, distress zone by Z″.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| XENE Xenon Pharmaceuticals Inc. compare | 37.8× |
| RLAY Relay Therapeutics, Inc. compare | 11.0× |
| TNGX Tango Therapeutics, Inc. compare | 9.9× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 9.5× |
| ACAD ACADIA Pharmaceuticals Inc. compare | 7.9× |
| ARQT Arcutis Biotherapeutics, Inc. | 7.0× |
| LEGN Legend Biotech Corporation Sponsored ADR compare | 4.5× |
| TLX Telix Pharmaceuticals Limited compare | 2.7× |
| VKTX Viking Therapeutics, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets